Switch theme
Sign up to access all valuation multiples
Akums Drugs and Pharmaceuticals Ltd a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services in India and overseas. Its services include formulation research and development (R&D), preparation and filing of regulatory dossiers in the Indian and Outside markets, and other testing services. It is also engaged in the manufacturing and sale of branded pharmaceutical formulations and active pharmaceutical ingredients (APIs). The operates in three segments: a) Contract Development and Manufacturing Operations (CDMO), b) Active Pharmaceutical Ingredient (API), and c) Branded and Generic formulations. Key revenue is generated from Contract Development and Manufacturing Operations (CDMO).
2004
16.1K+
LTM Revenue $476M
LTM EBITDA $57.7M
$738M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Akums has a last 12-month revenue of $476M and a last 12-month EBITDA of $57.7M.
In the most recent fiscal year, Akums achieved revenue of $467M and an EBITDA of $15.2M.
Akums expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Akums valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $404M | $467M | XXX | XXX | XXX |
| Gross Profit | $147M | $136M | XXX | XXX | XXX |
| Gross Margin | 37% | 29% | XXX | XXX | XXX |
| EBITDA | $35.9M | $15.2M | XXX | XXX | XXX |
| EBITDA Margin | 9% | 3% | XXX | XXX | XXX |
| Net Profit | -$29.1M | $11.0M | XXX | XXX | XXX |
| Net Margin | -7% | 2% | XXX | XXX | XXX |
| Net Debt | $35.2M | $56.4M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Akums's stock price is INR 434 (or $5).
Akums has current market cap of INR 66.5B (or $772M), and EV of INR 63.5B (or $738M).
See Akums trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $738M | $772M | XXX | XXX | XXX | XXX | $0.20 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Akums has market cap of $772M and EV of $738M.
Akums's trades at 1.6x LTM EV/Revenue multiple, and 12.8x LTM EBITDA.
Analysts estimate Akums's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Akums and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $738M | XXX | XXX | XXX |
| EV/Revenue | 1.6x | XXX | XXX | XXX |
| EV/EBITDA | 15.8x | XXX | XXX | XXX |
| P/E | 33.3x | XXX | XXX | XXX |
| P/E/Growth | 0.8x | XXX | XXX | XXX |
| EV/FCF | 37.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpAkums's NTM/LTM revenue growth is 11%
Akums's revenue per employee for the last fiscal year averaged $29K, while opex per employee averaged $8K for the same period.
Over next 12 months, Akums's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Akums's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Akums and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 16% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 10% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -58% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 21% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $29K | XXX | XXX | XXX | XXX |
| Opex per Employee | $8K | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 1% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 1% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 27% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Jubilant Pharmova | XXX | XXX | XXX | XXX | XXX | XXX |
| Biocon | XXX | XXX | XXX | XXX | XXX | XXX |
| Syngene International | XXX | XXX | XXX | XXX | XXX | XXX |
| Dishman Carbogen Amics | XXX | XXX | XXX | XXX | XXX | XXX |
| Suven Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Akums acquired XXX companies to date.
Last acquisition by Akums was XXXXXXXX, XXXXX XXXXX XXXXXX . Akums acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Akums founded? | Akums was founded in 2004. |
| Where is Akums headquartered? | Akums is headquartered in India. |
| How many employees does Akums have? | As of today, Akums has 16.1K+ employees. |
| Is Akums publicy listed? | Yes, Akums is a public company listed on BOM. |
| What is the stock symbol of Akums? | Akums trades under 544222 ticker. |
| When did Akums go public? | Akums went public in 2024. |
| Who are competitors of Akums? | Similar companies to Akums include e.g. Jubilant Pharmova, Biocon, Syngene International, Dishman Carbogen Amics. |
| What is the current market cap of Akums? | Akums's current market cap is $772M |
| What is the current revenue of Akums? | Akums's last 12-month revenue is $476M. |
| What is the current EBITDA of Akums? | Akums's last 12-month EBITDA is $57.7M. |
| What is the current EV/Revenue multiple of Akums? | Current revenue multiple of Akums is 1.6x. |
| What is the current EV/EBITDA multiple of Akums? | Current EBITDA multiple of Akums is 12.8x. |
| What is the current revenue growth of Akums? | Akums revenue growth between 2023 and 2024 was 16%. |
| Is Akums profitable? | Yes, Akums is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
